ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Novartis' melanoma combo fails in PhIII pharmatimes
August 24, 2020Novartis has announced that its investigational immunotherapy spartalizumab in combination with Tafinlar (dabrafenib) and Mekinist (trametinib) failed to improve progression-free survival in patients with advanced melanoma. -
Breztri Aerosphere cut rate of COPD exacerbations in PhIII trial pharmatimes
June 30, 2020AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) significantly cut the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with ... -
Sanofi, Alnylam’s RNAi therapeutic smashes PhIII targets
pharmatimes
September 22, 2017An investigational RNAi therapeutic being developed by Sanofi Genzyme and Alnylam Pharmaceuticals has hit targets in a late stage trial involving patients with hereditary ATTR amyloidosis with polyneuropathy.
Pharma Sources Insight January 2025
